DALLAS, June 26 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced that the Company gave an oral presentation yesterday on its monoclonal antibody product, Angiolix(R), at the 7th International Congress on Recombinant Antibodies, held in Dublin, Ireland. Dr. Agamemnon Epenetos, Access' Chief Scientific Officer -- Europe, presented data showing that Angiolix has the potential to prevent the growth of cancer stem cells.
Dr. Epenetos commented, "There is a growing body of evidence that indicates that tumor progression, dissemination and metastases result from cancer stem cells rather than the other cells which form the bulk of a cancer. As a result, therapies which attack these tumor cells will delay the onset of progression, but rarely cure the disease. Cancer stem cells are a subgroup of cancer cells that can be resistant to standard treatments, so agents like Angiolix, which have the potential to thwart cancer stem cells, hold great promise for the future treatment and eradication of cancer."
Access' monoclonal antibody product, Angiolix, blocks angiogenesis by inhibiting a novel receptor called lactadherin. Lactadherin causes angiogenesis through a VEGF dependent mechanism. Several other drugs have been developed or are in development to block VEGF and VEGF induced angiogenesis, such as Avastin.
In the presentation, Dr. Epenetos showed that Angiolix has been shown not only to block new blood vessels in tumors, in a similar manner to other anti VEGF drugs like Avastin, but that it could additionally have a direct killing effect on tumor cells potentially including cancer stem cells that are involved in angiogenesis and metastasis.
Access Pharmaceuticals is currently conducting key preclinical studies
at Imperial College London, UK to assess the efficacy of Angiolix in a wide
range of tumor models. These studies aim to demonstrate the potential
efficacy of Angiolix as a monotherapy and in com
|SOURCE Access Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved